首頁 > 市場調查報告書 > 製藥

生物製劑分子標靶治療學

T細胞結合雙特異性抗體（BsAbs）藥物市場規模、佔有率和成長分析：按標靶類型、腫瘤抗原、藥物類型、癌症類型、終端用戶產業和地區分類－2026-2033年產業預測

市場調查報告書

商品編碼

2160418

T細胞結合雙特異性抗體（BsAbs）藥物市場規模、佔有率和成長分析：按標靶類型、腫瘤抗原、藥物類型、癌症類型、終端用戶產業和地區分類－2026-2033年產業預測

T-cell Engaging BsAbs Drugs Market Size, Share, and Growth Analysis, By Target Type (CD3-Targeting, CD28-Targeting), By Tumor Antigen (CD19, BCMA), By Drug Type, By Cancer Type, By End-Use Industry, By Region - Industry Forecast 2026-2033

出版日期: 2026年09月22日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2024 年全球 T 細胞結合雙特異性抗體 (BsAbs) 藥物市值為 18 億美元，預計到 2025 年將成長至 21.3 億美元，到 2033 年將成長至 83 億美元，預測期（2026-2033 年）複合年成長率為 18.5%。

全球T細胞偶聯雙特異性抗體（BsAbs）市場代表癌症治療領域的一項重大進展，它透過靶向腫瘤抗原和T細胞上的CD3，克服了傳統療法面臨的抗藥性問題。這種創新方法備受關注，尤其是在血液系統惡性腫瘤治療領域取得成功後，其在固體癌治療方面也獲得了監管部門的批准，並吸引了更多投資者的目光。推動成長要素包括工程平台和臨床管線的進步，這些進步正在加速開發更有效的療法，同時降低風險。此外，人工智慧正在透過利用機器學習預測有效表位並簡化候選化合物的優先排序，從而變革標靶發現。這提高了臨床前模型的有效性，增強了市場信心，並最終為全球患者拓展了治療選擇。

全球T細胞結合雙特異性抗體（BsAbs）藥物市場的成長要素

蛋白質工程技術的進步顯著提升了抗體結構操控能力，從而親和性並最大限度地減少了脫靶效應。這些創新簡化了候選藥物的篩選流程，加速了臨床前試驗，有效縮短了研發週期。新型連接子技術的引入和穩定性的提升，使生產商能夠生產出更可靠的治療藥物批次。這些技術進步增強了投資者和醫療專業人士的信心，促使他們對雙特異性抗體計畫投入更多資金，並推動了未來用於臨床實踐的、前景廣闊的T細胞標靶治療研發管線的擴展。

全球T細胞結合雙特異性抗體（BSAB）藥物市場面臨的限制因素

T細胞結合雙特異性抗體的研發極為複雜，面臨許多挑戰，阻礙因素全球市場的發展。其複雜的結構設計需要先進的細胞株開發、精細的結合過程和嚴格的品質保證，進一步增加了生產的複雜性。從實驗室規模過渡到商業化生產往往會導致產量和產品均一性出現顯著差異，因此需要徹底改進製程。此外，製造商還需投入大量資金購買專用設備和聘請高技能人才，進而大幅增加營運成本。這些生產壁壘會延緩產品上市，阻礙中小企業進入市場，最終抑制市場成長。

全球T細胞靶向雙特異性抗體（BsAbs）藥物市場趨勢

全球T細胞偶聯雙特異性抗體（BsAbs）市場正經歷創新腫瘤治療產品線的顯著成長。在標靶檢驗精度提高和先進工程技術的推動下，製藥公司正日益開發針對固體癌和骨髓惡性腫瘤的BsAbs。這個快速成長的市場正在活性化大規模合作，聚合物藥物開發商渴望透過合作開發和授權協議來加速產品進入市場。隨著臨床成功率的提高，腫瘤科醫師對這類療法的信心日益增強，醫院和腫瘤治療網路也因此對尖端免疫調節療法的需求不斷成長，這些療法旨在為治療選擇有限的患者提供幫助。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太國家
拉丁美洲
- 墨西哥
- 巴西
- 其他拉丁美洲國家
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲國家

競爭資訊

前五大公司對比
主要公司2025年的市場定位
主要市場公司採取的策略
近期市場趨勢
企業市場占有率分析，2025 年
主要公司的完整公司簡介
- 公司詳情
- 產品系列分析
- 按細分市場進行企業市佔率分析
- 銷售收入年比比較（2023-2025 年）

主要公司簡介

Amgen
Regeneron Pharmaceuticals
Johnson & Johnson
AbbVie
Roche
Genmab
Merck & Co.
Pfizer
AstraZeneca
Sanofi
GSK
Xencor
MacroGenics
Janux Therapeutics
Harpoon Therapeutics
TeneoOne
Affimed
Ichnos Sciences
F-star Therapeutics
DualityBio

結論與建議

簡介目錄

Product Code: SQMIG35I3753

Global T-Cell Engaging Bsabs Drugs Market size was valued at USD 1.8 Billion in 2024 and is poised to grow from USD 2.13 Billion in 2025 to USD 8.3 Billion by 2033, growing at a CAGR of 18.5% during the forecast period (2026-2033).

The global market for T-cell engaging bispecific antibodies (BsAbs) represents a significant advancement in cancer therapeutics, offering unique mechanisms to target tumor antigens and CD3 on T cells, thereby overcoming resistance faced by traditional therapies. This innovative approach has gained traction, especially following successful applications in hematologic cancers, leading to regulatory approvals for solid tumors and heightened interest from investors. Key growth factors include advancements in engineering platforms and clinical pipelines, facilitating the development of more effective therapies with reduced risks. Moreover, AI is transforming target discovery by utilizing machine learning to predict effective epitopes and streamline candidate prioritization, enhancing preclinical models' relevance and fueling confidence in the market, ultimately expanding therapeutic options for patients worldwide.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global T-Cell Engaging Bsabs Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global T-Cell Engaging Bsabs Drugs Market Segments Analysis

Global t-cell engaging bsabs drugs market is segmented by target type, tumor antigen, drug type, cancer type, end-use industry and region. Based on target type, the market is segmented into CD3-Targeting, CD28-Targeting, Other T-Cell Targets and Others. Based on tumor antigen, the market is segmented into CD19, BCMA, DLL3, HER2, EGFR and Others. Based on drug type, the market is segmented into Bispecific T-Cell Engagers, Dual-Affinity Re-Targeting Antibodies and Other Bispecific Antibodies. Based on cancer type, the market is segmented into Hematological Malignancies, Solid Tumors and Others. Based on end-use industry, the market is segmented into Pharmaceutical Companies, Biotechnology Companies, Hospitals, Cancer Treatment Centers, Research Institutions and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global T-Cell Engaging Bsabs Drugs Market

The advancement of protein engineering technologies significantly enhances the ability to manipulate antibody structures, leading to improved affinity and minimized off-target effects. These innovations streamline the process of selecting candidates and expedite preclinical testing, effectively reducing the time needed for development. With the incorporation of novel linker technologies and advancements in stability, manufacturers are able to generate more reliable therapeutic batches. This technical progress cultivates greater confidence among investors and healthcare professionals, resulting in an increased investment in bispecific programs and a broadened pipeline of promising T-cell engaging therapies for the future clinical landscape.

Restraints in the Global T-Cell Engaging Bsabs Drugs Market

The intricate development of bispecific T-cell engaging antibodies presents several challenges that serve as restraints in the global market. The complex design necessitates advanced cell line development, meticulous conjugation processes, and stringent quality assurance, leading to increased production intricacies. Transitioning from laboratory-scale to commercial production often reveals significant variability in yield and product consistency, necessitating in-depth process enhancements. Additionally, manufacturers face the burden of investing in specialized machinery and highly skilled personnel, which significantly raises operational expenses. These manufacturing obstacles can prolong product launch schedules and discourage smaller enterprises from entering the market, ultimately restraining market growth.

Market Trends of the Global T-Cell Engaging Bsabs Drugs Market

The global T-cell engaging bispecific antibodies (BsAbs) market is witnessing a notable trend characterized by a surge in the adoption of innovative oncology pipelines. Pharmaceutical companies are increasingly advancing BsAbs targeting both solid tumors and hematologic malignancies, driven by enhanced target validation and sophisticated engineering technologies. This burgeoning landscape is prompting significant partnership activity, with large-molecule developers eager to enter co-development or licensing arrangements to expedite their market presence. As clinical success stories become more prevalent, oncologists are growing more confident in prescribing these therapies, ultimately boosting demand from hospitals and oncology networks that seek cutting-edge, immune-modulating treatment options for patients with limited alternatives.

Introduction

Objectives of the Study
Market Definition & Scope

Research Methodology

Research Process
Secondary & Primary Data Methods
Market Size Estimation Methods

Executive Summary

Global Market Outlook
Key Market Highlights
Segmental Overview
Competition Overview

Market Dynamics & Outlook

Macro-Economic Indicators
Drivers & Opportunities
Restraints & Challenges
Supply Side Trends
Demand Side Trends
Porter's Analysis & Impact
- Competitive Rivalry
- Threat of Substitutes
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factors
Market Impacting Factors
Top Investment Pockets
Ecosystem Mapping
Market Attractiveness Index 2025
PESTEL Analysis
Regulatory Landscape

Global T-cell Engaging BsAbs Drugs Market Size by Target Type & CAGR (2026-2033)

Market Overview
CD3-Targeting
CD28-Targeting
Other T-Cell Targets
Others

Global T-cell Engaging BsAbs Drugs Market Size by Tumor Antigen & CAGR (2026-2033)

Market Overview
CD19
BCMA
DLL3
HER2
EGFR
Others

Global T-cell Engaging BsAbs Drugs Market Size by Drug Type & CAGR (2026-2033)

Market Overview
Bispecific T-Cell Engagers
Dual-Affinity Re-Targeting Antibodies
Other Bispecific Antibodies

Global T-cell Engaging BsAbs Drugs Market Size by Cancer Type & CAGR (2026-2033)

Market Overview
Hematological Malignancies
Solid Tumors
Others

Global T-cell Engaging BsAbs Drugs Market Size by End-Use Industry & CAGR (2026-2033)

Market Overview
Pharmaceutical Companies
Biotechnology Companies
Hospitals
Cancer Treatment Centers
Research Institutions
Others

Global T-cell Engaging BsAbs Drugs Market Size & CAGR (2026-2033)

North America (Target Type, Tumor Antigen, Drug Type, Cancer Type, End-Use Industry)
- US
- Canada
Europe (Target Type, Tumor Antigen, Drug Type, Cancer Type, End-Use Industry)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Target Type, Tumor Antigen, Drug Type, Cancer Type, End-Use Industry)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Target Type, Tumor Antigen, Drug Type, Cancer Type, End-Use Industry)
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa (Target Type, Tumor Antigen, Drug Type, Cancer Type, End-Use Industry)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Amgen
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Regeneron Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Roche
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Genmab
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GSK
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Xencor
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
MacroGenics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Janux Therapeutics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Harpoon Therapeutics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
TeneoOne
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Affimed
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ichnos Sciences
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F-star Therapeutics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
DualityBio
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments